High-Risk Cancer Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting high-risk cancer clinical trials across 4 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Baltimore, Maryland, United States, Ganzhou, Jiangxi, China, Greenville, South Carolina, United States. Updated daily from ClinicalTrials.gov.


High-Risk Cancer Trials at a Glance

7 actively recruiting trials for high-risk cancer are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Baltimore, Ganzhou, and Greenville. Lead sponsors running high-risk cancer studies include Gee-Chen Chang, Jiangxi Provincial Cancer Hospital, and European Institute of Oncology.

Browse high-risk cancer trials by phase

Treatments under study

About High-Risk Cancer Clinical Trials

Looking for clinical trials for High-Risk Cancer? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new High-Risk Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about High-Risk Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal CarcinomaHigh-Risk CancerMaintenance Therapy
Jiangxi Provincial Cancer Hospital264 enrolled3 locationsNCT06277050
Recruiting

Prevent Cancer- Greenville

CancerHigh-Risk Cancer
Prisma Health-Upstate1,000 enrolled1 locationNCT04947098
Recruiting
Phase 2

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Prostate CancerBRCA1 MutationBRCA2 Mutation+2 more
Rana McKay, MD32 enrolled6 locationsNCT05498272
Recruiting
Phase 1

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Pancreatic CancerHigh-Risk Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins37 enrolled1 locationNCT05013216
Recruiting

Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration

Lung CancerSmokingFamily Relations+2 more
Gee-Chen Chang6,618 enrolled7 locationsNCT05557487
Recruiting
Phase 2

SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer

Rectal AdenocarcinomaHigh-Risk CancerMSS
Sixth Affiliated Hospital, Sun Yat-sen University49 enrolled1 locationNCT06908031
Recruiting

Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens

Anal CancerHigh-Risk CancerAnal Intraepithelial Neoplasia 2+1 more
European Institute of Oncology200 enrolled1 locationNCT06327568